NEW YORK (GenomeWeb News) — Systems Medicine, a wholly owned subsidiary of Cell Therapeutics, has penned a Cooperative Research and Development Agreement with the National Cancer Institute to develop targeted cancer drugs, Cell Therapeutics said today.
 
Specifically, the five-year alliance calls for the companies to research human monoclonal antibodies, peptides, and small molecules that affect signal transduction through the insulin-like growth factor receptor type I and the insulin receptor.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.